AcuCort AB (Spotlight Stock Market: ACUC) today announced that the United States Patent and Trademark Office (USPTO) has granted the company’s drug ISICORT® trademark protection. AcuCort has an active strategy for the company’s trademarks that covers all major geographic markets, including the US.
ISICORT® is a thin, fast-dissolving and user-friendly oral film for the treatment of acute and severe allergic reactions, for croup in children and chemotherapy-induced nausea and vomiting (CINV). The fast-dissolving oral film contains the glucocorticoid dexamethasone which is a well-known, often used and well-documented anti-inflammatory substance. In October 2020, ISICORT® received market approval by the Swedish Medical Products Agency.
“We are very pleased that AcuCort has been granted trademark protection for ISICORT® in the USA. The decision means that we now have a registered trademark with associated trademark protection in the world’s largest pharmaceutical market. Furthermore, our partner dialogues, preparations for commercialization and the work to achieve market approval in more markets continues as planned, says Jonas Jönmark, CEO of AcuCort AB.
For more information, please contact
Jonas Jönmark, CEO, AcuCort AB
Telephone: + 46 (0)70 365 5400
Email: jonas.jonmark@acucort.se